Vigabatrin therapy in six patients with succinic semialdehyde dehydrogenase deficiency

J Inherit Metab Dis. 1995;18(2):143-6. doi: 10.1007/BF00711750.
No abstract available

MeSH terms

  • 4-Aminobutyrate Transaminase / antagonists & inhibitors
  • Aldehyde Oxidoreductases / deficiency*
  • Brain Diseases, Metabolic / complications
  • Brain Diseases, Metabolic / drug therapy
  • GABA Antagonists / adverse effects
  • GABA Antagonists / therapeutic use*
  • Humans
  • Metabolism, Inborn Errors / complications
  • Metabolism, Inborn Errors / drug therapy*
  • Seizures / chemically induced
  • Sodium Oxybate / cerebrospinal fluid
  • Succinate-Semialdehyde Dehydrogenase
  • Treatment Outcome
  • Vigabatrin
  • gamma-Aminobutyric Acid / adverse effects
  • gamma-Aminobutyric Acid / analogs & derivatives*
  • gamma-Aminobutyric Acid / cerebrospinal fluid
  • gamma-Aminobutyric Acid / therapeutic use

Substances

  • GABA Antagonists
  • gamma-Aminobutyric Acid
  • Sodium Oxybate
  • Aldehyde Oxidoreductases
  • ALDH5A1 protein, human
  • Succinate-Semialdehyde Dehydrogenase
  • 4-Aminobutyrate Transaminase
  • Vigabatrin